NVAX Live signals | Maximize Profits with Getagraph.com

SELL 62193 min ago

@ $5.28

Issued: 13 Mar 2024 @ 14:02

Return: -25.20%

Previous signal: Mar 13 - 13:12

Previous signal: Buy

Return: 1.36 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
Today's Volume	3.34M
Average Volume	7.22M
Market Cap	552.81M
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.730
ATR14	$0.00900 (0.23%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.97
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

Volume Correlation

Long: -0.07 (neutral)

Short: -0.96 (very strong negative)

Signal:(57.849) Neutral

Novavax Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novavax Inc Correlation - Currency/Commodity

0.30
( neutral )

0.05
( neutral )

0.00
( neutral )

0.44
( neutral )

-0.28
( neutral )

Novavax Inc Financials

Annual	2023
Revenue:	$983.71M
Gross Profit:	$704.24M (71.59 %)
EPS:	$-5.41

Q4	2023
Revenue:	$291.34M
Gross Profit:	$142.47M (48.90 %)
EPS:	$-1.440

Q3	2023
Revenue:	$22.06M
Gross Profit:	$-76.87M (-348.37 %)
EPS:	$-1.260

Q2	2023
Revenue:	$424.43M
Gross Profit:	$368.65M (86.86 %)
EPS:	$0.650

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.